We’re excited to share that Biocytogen will attend the 23rd CIMT Annual Meeting in Mainz, Germany from May 11th - 13th. This is the largest cancer immunotherapy conference in Europe, boasting roughly 1000 attendees from industry, academia, and regulatory bodies. This year’s program will delve into advances in cellular therapies and immune-cancer interactions. Come meet our team at booth #16 to learn about our latest scientific breakthroughs and innovative mouse models.
What is CIMT?
Founded in 2002, The Association for Cancer Immunotherapy (CIMT) is a not-for-profit organization that aims to encourage the development and translation of cancer immunotherapies through annual events, educational seminars, workshops, and partnerships. It creates stimulating forums for its members to exchange knowledge and discoveries, promoting collaboration across multiple fields and the education of next-generation healthcare professionals.
Event Overview
Date: May 11th - 13th, 2026
Venue: Rheingoldhalle Mainz, Rheinstraße 66, 55116 Mainz, Germany
Event Schedule
For more information, please refer to the event program.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
Let’s accelerate the development of immunotherapy treatments together. We look forward to connecting with you in Mainz, Germany!
